



Programme en maladies infectieuses et immunité en santé mondiale Infectious Diseases and Immunity in Global Health Program

La recherche pour le bénéfice de la santé mondiale Improving Global Health through Research

Séminaire conjoint / Joint seminar

IDIGH









12 juin / June 12 (13:00)

1001 boul. Décarie, Bloc E, EM1.3509



Jorge Kalil MD, PhD, FRCP, Dr.h.c.

Distinguished Visiting Professor Evergrande Center for Immunologic Diseases, Harvard Medical School

Professor of Clinical Immunology and Allergy University of São Paulo

Development and clinical trial of an attenuated tetravalent dengue vaccine

There are over 300 million cases of dengue worldwide per year. Some are serious and even fatal. The disease burden occurs in tropical and subtropical areas. There is no treatment and the licensed vaccine does not provide the proper protection. NIH, in collaboration with Brazilian institutions, has been developing a tetravalent attenuated dengue vaccine. Brazil is responsible for industrial and clinical development. Currently in phase 3 clinical trial, more than 17,000 volunteers have been recruited. The talk will present the scientific results.